학술논문

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
Document Type
Article
Source
In: The Lancet Oncology. (The Lancet Oncology, July 2022, 23(7):919-930)
Subject
Language
English
ISSN
14745488
14702045